IDStewardship
DECEMBER 1, 2022
In this article a pharmacist with advanced training and experience in infectious diseases discusses five things pharmacists should know about ventilator associated pneumonia (VAP). Authored By: Lucia Rose, PharmD, BCIDP. Article Posted 1 December 2022.
PharmaVoice
DECEMBER 1, 2022
Why South Rampart Pharma’s novel new molecule could be a key to solving the global pain epidemic
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
DECEMBER 1, 2022
DeepTCR system showed efficacy as a predictive clinical tool and provided information on the biological mechanisms that underlie how patients respond to immunotherapy.
PharmaVoice
DECEMBER 1, 2022
A potential flurry of regulatory activity could be on the horizon yet this year — and several key drug approvals are at stake
Pharmacy Times
DECEMBER 1, 2022
Live-jslm (Rebyota; Ferring Pharmaceuticals) is indicated for the prevention of recurring Clostridioides difficile infection among patients 18 years of age and older after an antibiotic treatment.
Fierce Healthcare
DECEMBER 1, 2022
As major hospitals now bill for some patient-provider messaging, the move could usher wider adoption. dmuoio. Thu, 12/01/2022 - 17:48
Pharmacy Times
DECEMBER 1, 2022
Investigators model 2 hypothetical cities as interconnected networks with a combined population of 100,000 bisexual, gay, and other men who have sex with men.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharmacy Times
DECEMBER 1, 2022
Individuals who had COVID-19 were 55% more likely to develop epilepsy or seizures over the following 6 months than those who had influenza.
Fierce Healthcare
DECEMBER 1, 2022
UnitedHealth, American Nurses Foundation team on pilot to tackle nurse burnout. pminemyer. Thu, 12/01/2022 - 16:56
Pharmacy Times
DECEMBER 1, 2022
Data suggest that few US adults are aware that wine can increase the risk of cancer.
Fierce Pharma
DECEMBER 1, 2022
With FDA nod for its fecal microbiome therapy, Ferring becomes No. 1 in No. kdunleavy. Thu, 12/01/2022 - 10:14
Pharmacy Times
DECEMBER 1, 2022
Commonly known as “relationship addiction,” co-dependency involves emotional, spiritual, physical, or mental enmeshment with a loved one.
Fierce Healthcare
DECEMBER 1, 2022
Senators to Medicare Advantage plans: Get your provider directories in order. rking. Thu, 12/01/2022 - 16:41
Pharmacy Times
DECEMBER 1, 2022
The investigational drug is a monoclonal antibody with a high affinity and specificity for cancer-specific plectin, a cell surface protein that correlates with aggressive tumors and poor prognosis.
Fierce Pharma
DECEMBER 1, 2022
Eli Lilly dumps Innovent's PD-1 after FDA rebuff, nixing high-profile Chinese cancer drug. Thu, 12/01/2022 - 15:03
Pharmacy Times
DECEMBER 1, 2022
Patient selection is a key factor in the safe and effective administration of advanced pain management modalities.
Fierce Healthcare
DECEMBER 1, 2022
Rough investments, rising costs push Cleveland Clinic's 9-month losses past $1.5B. dmuoio. Thu, 12/01/2022 - 15:00
Pharmacy Times
DECEMBER 1, 2022
Data from the fourth interim analysis of the ARC-7 trial shows that a combination of Fc-silent anti-TIGIT and anti-PD-1 molecules are effective for objective response rates in certain lung cancers.
Fierce Pharma
DECEMBER 1, 2022
PureTech readies oral CBD capsule for clinic to challenge Jazz’s Epidiolex. ntaylor. Thu, 12/01/2022 - 11:05
Pharma Phorum
DECEMBER 1, 2022
Lack of access, strict regulations, and demanding schedules have made it extremely difficult for patients to participate in clinical trials.
Fierce Pharma
DECEMBER 1, 2022
Roche, having shared data with regulators, unwraps results of subcutaneous Tecentriq phase 3 trial. ntaylor. Thu, 12/01/2022 - 09:45
Pharmaceutical Technology
DECEMBER 1, 2022
The US Food and Drug Administration (FDA) has granted approval for Ferring Pharmaceuticals’ faecal microbiota product, Rebyota, to prevent Clostridioides difficile infection (CDI) recurrence in people aged 18 years and above.
Pharmafile
DECEMBER 1, 2022
Switzerland-based Ferring Pharmaceuticals announced the FDA has approved its biotherapeutic REBYOTA®, indicated for the prevention of recurrence of Clostridioides difficile infection (CDI) in patients over the age of eighteen, following antibiotic treatment.
Fierce Healthcare
DECEMBER 1, 2022
Is Digital Health Closing Gaps in Health Equity? ncapone. Thu, 12/01/2022 - 12:54
Pharmafile
DECEMBER 1, 2022
Pulmonx, a US-based medical technology company, has secured approval from the Japanese Ministry of Health, Labour, and Welfare (MHLW) for its Zephyr Endobronchial Valve, used to treat patients with severe chronic obstructive pulmonary disease (COPD) or emphysema. read more. Medical Communications
Fierce Healthcare
DECEMBER 1, 2022
Texas docs file latest legal challenge to surprise billing rule, arguing arbitration process unfair. rking. Thu, 12/01/2022 - 14:43
Pharmafile
DECEMBER 1, 2022
The FDA have announced that Eli Lilly’s COVID-19 drug bebtelovimab is not authorised for emergency use in the US, as it is not expected to neutralise the dominant Omicron BQ.1 and BQ.1.1 subvariants.
Pharma Phorum
DECEMBER 1, 2022
In the newest episode of the pharmaphorum podcast, editor in chief Jonah Comstock chats with Gita Barry, EVP and GM of Immersive Healthcare at Penumbra, a therapeutic VR company.
European Pharmaceutical Review
DECEMBER 1, 2022
Results from a Phase II/III study , published in The Lancet , showed a single, oral dose of acoziborole was up to 95 percent successful in treating sleeping sickness (human African trypanosomiasis). About the Phase II/III study.
Fierce Healthcare
DECEMBER 1, 2022
Omicron wave greatly increased infant hospitalization, says CDC. fdiamond. Thu, 12/01/2022 - 12:02
European Pharmaceutical Review
DECEMBER 1, 2022
According to GlobalData’s recent report , a total of five marketed messenger RNA (mRNA) non-vaccine products by 2028 will generate over $2 billion, generated by the approval of pipeline agents.
Pharmafile
DECEMBER 1, 2022
Neuralink owner Elon Musk announced that he has submitted paperwork to the FDA which he hopes will allow Neuralink to undertake human trials in 2023.
Pharma Mirror
DECEMBER 1, 2022
QS-21 in blockbuster Shingles vaccine, first vaccine approved for Malaria, promising RSV phase III candidate, and Covid-19 applications. Botanical Solution Inc.
European Pharmaceutical Review
DECEMBER 1, 2022
Rebyota, the first faecal microbiota product to prevent recurrence of Clostridioides difficile infection (CDI) in people 18 years and older after being given antibiotics for recurrent CDI, has been approved by the US Food and Drug Administration (FDA).
Fierce Healthcare
DECEMBER 1, 2022
UpStream nabs $140M to expand nationwide, scale up value-based care services. agliadkovskaya. Thu, 12/01/2022 - 14:10
Pharma Phorum
DECEMBER 1, 2022
Myeloma Patients Europe (MPE) has identified significant inequalities among patients’ access to myeloma clinical trials in Central and Eastern Europe (CEE) in a first-of-its-kind advocacy report.
Pharmacy Times
DECEMBER 1, 2022
With the advent of disease-modifying therapies, the life span of patients with multiple sclerosis has increased dramatically.
Expert insights. Personalized for you.
275 
Let's personalize your content